Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGENUS INCAGEN · Entity 5774 | Chief Strategy Officer | July 23, 2019 | July 25, 2019 |
| Tectonic Therapeutic, Inc.TECX · Entity 5328 | Chief Operating Officer | June 20, 2024 | June 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGENUS INC
Report date July 23, 2019 · Filed July 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.39 · Expires 2029-07-23 | Direct | 18,333 |
Reported balance
After 2019-07-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-23 · Grant · Acquired 18,333 · Balance 18,333 F1: Stock option awarded in accordance with Agenus Inc. 2019 Equity Incentive Plan and is eligible to vest, if at all, in a single installment on June 30, 2022 based upon the Company stock price performance. Amount shown reflects the target award. The ultimate award size can range between 0% and 150% of target based on the actual average stock price achieved at the end of the performance period. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option awarded in accordance with Agenus Inc. 2019 Equity Incentive Plan and is eligible to vest, if at all, in a single installment on June 30, 2022 based upon the Company stock price performance. Amount shown reflects the target award. The ultimate award size can range between 0% and 150% of target based on the actual average stock price achieved at the end of the performance period.
Tectonic Therapeutic, Inc.
Report date June 20, 2024 · Filed June 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,368 |
Reported balance
After 2024-06-20 transaction · row 1
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 126,368 · Balance 126,368 F1: Received in exchange for 236,458 shares of common stock of Tectonic Therapeutic, Inc., a Delaware corporation ("Tectonic"), pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of Tectonic common stock was converted into the right to receive 0.534419990 shares of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2031-06-27 | Direct | 56,061 |
Reported balance
After 2024-06-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-20 · Grant · Acquired 56,061 · Balance 56,061 F2: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F4: Received in exchange for a stock option to acquire 104,901 shares of Tectonic common stock pursuant to the Merger Agreement. F3: 22,508 shares subject to the option are fully vested. The remaining shares subject to the option vest in 10 equal monthly installments beginning on June 30, 2024, such that the option will be fully vested on March 31, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.38 · Expires 2033-11-30 | Direct | 18,704 |
Reported balance
After 2024-06-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-20 · Grant · Acquired 18,704 · Balance 18,704 F2: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F6: Received in exchange for a stock option to acquire 35,000 shares of Tectonic common stock pursuant to the Merger Agreement. F5: The shares subject to the option vest in 48 equal monthly installments beginning on December 1, 2023, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Received in exchange for 236,458 shares of common stock of Tectonic Therapeutic, Inc., a Delaware corporation ("Tectonic"), pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of Tectonic common stock was converted into the right to receive 0.534419990 shares of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc.
F2: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split.
F3: 22,508 shares subject to the option are fully vested. The remaining shares subject to the option vest in 10 equal monthly installments beginning on June 30, 2024, such that the option will be fully vested on March 31, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F4: Received in exchange for a stock option to acquire 104,901 shares of Tectonic common stock pursuant to the Merger Agreement.
F5: The shares subject to the option vest in 48 equal monthly installments beginning on December 1, 2023, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F6: Received in exchange for a stock option to acquire 35,000 shares of Tectonic common stock pursuant to the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2024 Filed Jun 24, 2024 20:16 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,704 | Not disclosed Strike: $5.38 | Not disclosed |
DisclosureSEC source: 0001415889-24-017954 · form4-06242024_080632.xml · derivative · entry 3 Cortis Christian · CIK 0001744495 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,704 Underlying: Common Stock · 18,704 shares Expires 2033-11-30 F2 · derivative.exercise_price: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F2 · shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F2 · price: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F6 · price: Received in exchange for a stock option to acquire 35,000 shares of Tectonic common stock pursuant to the Merger Agreement. F5 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on December 1, 2023, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F2 · derivative.underlying_shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:16 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantEmployee Stock Option (Right to Buy) · Derivative | 56,061 | Not disclosed Strike: $2.38 | Not disclosed |
DisclosureSEC source: 0001415889-24-017954 · form4-06242024_080632.xml · derivative · entry 2 Cortis Christian · CIK 0001744495 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,061 Underlying: Common Stock · 56,061 shares Expires 2031-06-27 F2 · derivative.exercise_price: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F2 · shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F2 · price: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F4 · price: Received in exchange for a stock option to acquire 104,901 shares of Tectonic common stock pursuant to the Merger Agreement. F3 · derivative.exercise_date: 22,508 shares subject to the option are fully vested. The remaining shares subject to the option vest in 10 equal monthly installments beginning on June 30, 2024, such that the option will be fully vested on March 31, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F2 · derivative.underlying_shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:16 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantCommon Stock | 126,368 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-017954 · form4-06242024_080632.xml · nonDerivative · entry 1 Cortis Christian · CIK 0001744495 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,368 F1 · price: Received in exchange for 236,458 shares of common stock of Tectonic Therapeutic, Inc., a Delaware corporation ("Tectonic"), pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of Tectonic common stock was converted into the right to receive 0.534419990 shares of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc. Read SEC document |
| July 23, 2019 Filed Jul 25, 2019 23:32 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option (Right to buy) · Derivative | 18,333 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001745285-19-000011 · primary_doc.xml · derivative · entry 1 Cortis Christian · CIK 0001744495 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,333 Underlying: Common Stock · 18,333 shares Expires 2029-07-23 F1 · derivative.exercise_date: Stock option awarded in accordance with Agenus Inc. 2019 Equity Incentive Plan and is eligible to vest, if at all, in a single installment on June 30, 2022 based upon the Company stock price performance. Amount shown reflects the target award. The ultimate award size can range between 0% and 150% of target based on the actual average stock price achieved at the end of the performance period. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 21:31 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option(right to buy) · Derivative | 135,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0000899243-19-017837 · doc4.xml · derivative · entry 1 Cortis Christian · CIK 0001744495 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2029-01-01 F1 · derivative.exercise_date: Option was granted on January 1, 2019, subject to shareholder approval of the Company's 2019 Equity Incentive Plan, which was obtained at the Company's annual shareholder meeting on June 19,2019. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan. Option vests over a three year period, with 1/3 of Option vesting on January 1, 2020, and the balance vesting in equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.